Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

By | September 28, 2021
Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).